porcilis parvo inj. emuls. i.m.
intervet international - porcine parvovirus (inactivated) 9 log2 hi/dose - emulsion for injection - porcine parvovirus - porcine parvovirus - pig
progressis inj. emuls. i.m. vial
ceva santé animale sa-nv - porcine reproductive and respiratory syndrome virus (inactivated) - emulsion for injection - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - porcine reproductive and respiratory syndrome (prrs) virus - pig
progressis emulsion for injection
kernfarm - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - emulsion for injection - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - porcine reproductive and respiratory syndrome (prrs) virus - pig
reprocyc prrs eu inj. susp. (lyoph.) i.m. vial
boehringer ingelheim vetmedica gmbh - porcine reproductive and respiratory syndrome virus (live, attenuated) - lyophilisate and solvent for suspension for injection - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - porcine reproductive and respiratory syndrome (prrs) virus - pig
reprocyc prrs eu et impranflex inj. susp. (lyoph. + solv.) i.m. vial
boehringer ingelheim vetmedica gmbh - porcine reproductive and respiratory syndrome virus (live, attenuated) - lyophilisate and solvent for suspension for injection - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - porcine reproductive and respiratory syndrome (prrs) virus - pig
suvaxyn parvo/e-amphigen inj. emuls. i.m. vial
zoetis belgium sa-nv - porcine parvovirus ; erysipelothrix rhusiopathiae (inactivated) - emulsion for injection - porcine parvovirus; erysipelothrix rhusiopathiae, inactivated - porcine parvovirus + erysipelothrix - pig
unistrain prrs inj. susp. (lyoph. + solv.) i.m./i.derm. vial
laboratorios hipra s.a. - porcine reproductive and respiratory syndrome virus (live, attenuated) - lyophilisate and solvent for suspension for injection - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - porcine reproductive and respiratory syndrome (prrs) virus - pig
persovac inj. susp. (lyoph.) i.m. vial
ceva santé animale sa-nv - porcine reproductive and respiratory syndrome virus (live, attenuated) - lyophilisate for suspension for injection - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - porcine reproductive and respiratory syndrome (prrs) virus - pig
fixr prrs inac inj. emuls. i.m. vial
kernfarm b.v. - porcine reproductive and respiratory syndrome virus (inactivated) ; porcine reproductive and respiratory syndrome virus (inactivated) - emulsion for injection - porcine respiratory and reproductive syndrome virus (prrsv), live, attenuated - porcine reproductive and respiratory syndrome (prrs) virus - pig
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.